Aktienanalyse zu Agenus Inc (AGEN)AGENAgenus Inc

Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Agenus Inc is a good buy right now due to its recent financial improvement, with a net income of $0.6 million for Q2 2026 compared to a net loss of $30 million in the same period last year. The stock is currently priced at $7.66, which is significantly lower than the analyst price target of $25, indicating a potential upside of over 226%. Additionally, the company has shown strong revenue growth, increasing from $25.7 million to $34.5 million in the last quarter, driven by promising product sales. However, the main risk is the negative net income margin of -1.64% for Q2 2026, which indicates ongoing financial challenges that investors should monitor closely.

3 analysts cover AGEN: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 23.00.